drug_type
RELEVANT_DRUG
intervention_type
bispecific T-cell–engaging antibody (biologic)
drug_description
Subcutaneous bispecific T‑cell–engaging antibody (BCMA×CD3) that redirects cytotoxic T cells to BCMA-expressing myeloma cells to induce lysis.
nci_thesaurus_concept_id
C146860
nci_thesaurus_preferred_term
Elranatamab
nci_thesaurus_definition
A bispecific monoclonal antibody against human CD3, a T-cell surface antigen, and human B-cell maturation antigen (BCMA; TNFRSF17), a tumor-associated antigen (TAA) expressed on plasma cells, with potential antineoplastic activity. Upon administration, elranatamab binds to both CD3 on T-cells and BCMA expressed on malignant plasma cells. This results in the cross-linking of T-cells and tumor cells, and induces a potent cytotoxic T-lymphocyte (CTL) response against BCMA-expressing plasma cells. BCMA, a member of the tumor necrosis factor receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival.
drug_category
BISPECIFIC T ENGAGER
drug_class
Engager
drug_delivery_route
Subcutaneous
drug_mechanism_of_action
Bispecific antibody targeting BCMA on myeloma cells and CD3 on T cells; crosslinks T cells to BCMA-positive plasma cells to form an immune synapse, activate cytotoxic T lymphocytes, and induce perforin/granzyme-mediated tumor cell lysis.
drug_name
Elranatamab
nct_id_drug_ref
NCT06152575